Grateful
Recent MIRA News
- Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission • PR Newswire (US) • 04/02/2024 12:00:00 PM
- MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor • PR Newswire (US) • 03/21/2024 03:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:45:16 PM
- MIRA Pharmaceuticals Provides Corporate Update • PR Newswire (US) • 02/05/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/27/2023 10:33:10 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/27/2023 10:27:24 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:50:37 PM
- MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations • PR Newswire (US) • 12/04/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 10:00:35 PM
- MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% • PR Newswire (US) • 11/29/2023 01:00:00 PM
- MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time • PR Newswire (US) • 11/21/2023 03:42:00 PM
- MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a • PR Newswire (US) • 11/21/2023 03:09:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/20/2023 09:18:46 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2023 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:10:31 PM
- MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 • PR Newswire (US) • 11/20/2023 01:00:00 PM
- MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot • PR Newswire (US) • 09/18/2023 12:30:00 PM
- MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts • PR Newswire (US) • 09/05/2023 12:31:00 PM
- MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit • PR Newswire (US) • 08/31/2023 12:31:00 PM
- MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time • PR Newswire (US) • 08/29/2023 03:39:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM